Osteoporosis is a silent disease caused by low bone mineral density and is complicated by fractures. This study was designed to examine the differentiation of uterine stem cell-derived osteoprogenitor cells (UOPCs) both in vitro and in vivo, assessing their effectiveness in treating osteoporosis. CD271⁺/CD45⁻ UOPCs were isolated from the endometrial tissue of inbred Balb/c mice through magnetic activated cell sorting. Stem cell differentiation assays were used for CD271⁺/CD45⁻ UOPCs in vitro. In vivo, the UOPCs were implanted into mouse osteoporosis models through tail-vein injection for 8 weeks. Osteogenic differentiation was examined by X-rays and computed tomography (CT) scans. Enhanced green fluorescent protein (EGFP)-labeled UOPCs, obtained from C57BL/6-Tg (ACTb-EGFP) 1Osb/J mice, were used to assess cell survival in the osteoporosis model. The levels of osteogenic markers were assessed by enzyme-linked immunosorbent assay. In vitro, UOPCs were able to form into typical spheres and various differentiations. In vivo, implantation of UOPCs into osteoporosis model significantly increased bone mineral densities and bone microstructure parameters. The levels of a biochemical marker of bone metabolism, Semaphorin-3A, increased significantly. However, levels of receptor activator of nuclear factor kappa-B ligand decreased. Immunofluorescence staining of osteoporosis mice injected with green fluorescent protein+ UOPCs showed their survival for up to 7 days. In conclusion, stem cells with osteogenic differentiation potential can be isolated from uterine or endometrial tissue. These UOPCs can stably proliferate and differentiate in vitro or in vivo, which can inhibit bone resorption and osteoclast marker expression. In vivo, UOPCs significantly improved reduction in bone density caused by reduced estrogen levels. Such cell transplantation approach is potentially useful in the treatment of osteoporosis.

中文翻译：

---

小鼠子宫间充质干细胞及其对骨质疏松症的治疗作用

骨质疏松症是一种由低骨密度引起的无症状疾病，并伴有骨折。本研究旨在检查子宫干细胞衍生的骨祖细胞 (UOPCs)在体外和体内的分化，评估其治疗骨质疏松症的有效性。CD271 ⁺ /CD45 ^- UOPCs 通过磁激活细胞分选从近交系 Balb/c 小鼠的子宫内膜组织中分离出来。干细胞分化试验用于体外CD271 ⁺ /CD45 ^- UOPCs 。体内，通过尾静脉注射将UOPCs植入小鼠骨质疏松模型8周。通过 X 射线和计算机断层扫描 (CT) 扫描检查成骨分化。从 C57BL/6-Tg (ACTb-EGFP) 1Osb/J 小鼠获得的增强型绿色荧光蛋白 (EGFP) 标记的 UOPC 用于评估骨质疏松症模型中的细胞存活率。通过酶联免疫吸附测定评估成骨标志物的水平。在体外，UOPCs 能够形成典型的球体和各种分化。在体内，将 UOPCs 植入骨质疏松症模型显着增加了骨矿物质密度和骨微结构参数。骨代谢生化标志物Semaphorin-3A 的水平，显着增加。然而，核因子κ-B 配体的受体激活剂水平降低。注射绿色荧光蛋白 + UOPCs 的骨质疏松症小鼠的免疫荧光染色显示它们的存活时间长达 7 天。总之，具有成骨分化潜能的干细胞可以从子宫或子宫内膜组织中分离出来。这些UOPCs可以在体外或体内稳定增殖和分化，可以抑制骨吸收和破骨细胞标志物的表达。在体内，UOPCs 显着改善了由雌激素水平降低引起的骨密度降低。这种细胞移植方法可能用于治疗骨质疏松症。